CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

BACKGROUND: Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinoma (ccRCC) with a median time to progression shorter than 1 year. The objective is to discover predictive markers of response to adapt the treatment at diagnosis. METHODS: Prospective phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Dufies, Maeva, Giuliano, Sandy, Viotti, Julien, Borchiellini, Delphine, Cooley, Linsay S, Ambrosetti, Damien, Guyot, Mélanie, Ndiaye, Papa Diogop, Parola, Julien, Claren, Audrey, Schiappa, Renaud, Gal, Jocelyn, Frangeul, Antoine, Jacquel, Arnaud, Cassuto, Ophélie, Grépin, Renaud, Auberger, Patrick, Bikfalvi, Andréas, Milano, Gérard, Escudier, Bernard, Rioux-Leclercq, Nathalie, Porta, Camillo, Negrier, Sylvie, Chamorey, Emmanuel, Ferrero, Jean-Marc, Pagès, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625677/
https://www.ncbi.nlm.nih.gov/pubmed/28850564
http://dx.doi.org/10.1038/bjc.2017.276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625677/
https://www.ncbi.nlm.nih.gov/pubmed/28850564
http://dx.doi.org/10.1038/bjc.2017.276

Ejemplares similares